✦ LIBER ✦

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting

✍ Scribed by Guérin, Annie; Chen, Lei; Wu, Eric Q.; Ponce de Leon, Diego; Griffin, James D.

Book ID: 111914041
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 174 KB
Volume: 28
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007995.2012.705264

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity and tolerability of nilotinib :

Activity and tolerability of nilotinib : A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant

✍ Maya Koren-Michowitz; Philipp le Coutre; Justus Duyster; Christof Scheid; Panayi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

## Abstract ## BACKGROUND: Nilotinib is active in imatinib‐resistant and ‐intolerant chronic myeloid leukemia patients and was recently approved for these indications. ## METHODS: Data on the efficacy and safety of nilotinib treatment were collected from 2 phase 2 expanded access clinical trials

Erratum: Activity and Tolerability of Ni

Erratum: Activity and Tolerability of Nilotinib: A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant

✍ Maya Koren-Michowitz; Philipp le Coutre; Justus Duyster; Christof Scheid; Panayi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB

Nilotinib in imatinib-resistant or imati

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

✍ Giles, F J; le Coutre, P D; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottman 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 383 KB

Lack of non-hematological cross intolera

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

✍ Yukio Kobayashi; Hisashi Sakamaki; Shin Fujisawa; Kiyoshi Ando; Kazuhito Yamamot 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 152 KB

Dasatinib, even at low doses, is an effe

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

✍ Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB

PSY17 THE COST AND COST EFFECTIVENESS OF

PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO

✍ A Juarez-Garcia; L Zapata; G Vega; J Idrovo; R Rivas; JL Kramis; G Litalien; S R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB